Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14555MR)

This product GTTS-WQ14555MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14555MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10253MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ13469MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ12467MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ10542MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ11902MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ4235MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ3338MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ4352MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW